Trial · NCT07891364
GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT07891364, Early phase 1, Not yet recruiting, RenJi Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease. Trials, record NCT07891364. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891364
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease
- NCT number
- NCT07891364
- Status
- Not yet recruiting
- Phases
- Early phase 1
- Enrollment
- 24 participants, estimated
- Lead sponsor
- RenJi Hospital
- Conditions
- Autosomal Dominant Polycystic Kidney
- Interventions
- GBP-213
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and tolerability of GBP-213 in patients with rapidly progressive ADPKD | From first treatment (Week 1, Day 1) to 12 months after the last dose (Week 13, Day 1) | The incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and their relationship to the investigational drug |
| Secondary | Area under the plasma concentration-time curve from time zero to the last measurable time point (AUC0-t) | From first dose (Week 1, Day 1) to the last dose (Week 13, Day 1) | |
| Secondary | Area under the plasma concentration-time curve from time zero to infinity (AUC0-∞) | From first dose (Week 1, Day 1) to the last dose (Week 13, Day 1) | |
| Secondary | Maximum plasma concentration (Cmax) | From first dose (Week 1, Day 1) to the last dose (Week 13, Day 1) | |
| Secondary | Time to maximum plasma concentration (Tmax) | From first dose (Week 1, Day 1) to the last dose (Week 13, Day 1) | |
| Secondary | Terminal elimination half-life (t1/2z) | From first dose (Week 1, Day 1) to the last dose (Week 13, Day 1) | |
| Secondary | Apparent clearance (CLz) | From first dose (Week 1, Day 1) to the last dose (Week 13, Day 1) | |
| Secondary | Apparent volume of distribution (Vz) | From first dose (Week 1, Day 1) to the last dose (Week 13, Day 1) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891364
GET https://conductscience.org/api/trials/v1/NCT07891364/registered